Specialty distributor skillset quantified

New research shows that specialty drug distributors save the healthcare industry $3.5 billion compared with the cost projected when manufacturers and healthcare providers do the job. The savings reach $8 billion when researchers factor in traditional drug distributors that handle the cancer, biotech and other drugs requiring low-tolerance, in-transit conditions.

High-tech, cold-chain and just-in-time delivery skills separate specialty distributors from other drug handlers, says the Center for Healthcare Supply Chain Research, a foundation of the Healthcare Distribution Management Association. Consultant Arthur D. Little conducted the study.

Techniques for preserving delicate medicines and an array of value-added services further separate the specialists from traditional drug handlers.

Big-name distributors appear to be aware of the chink in their armor. Both AmerisourceBergen and Cardinal have proclaimed recently a specialty drug distribution objective, as reported Tuesday.

- see the release

Special Report: The Big 3 Distributors

Suggested Articles

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.

India’s Aurobindo, which has yet to close its $1 billion deal to buy 300 Sandoz products in the U.S., continues to rack up FDA issues.